Position in ANAB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$295,852
+$52,772 QoQ
Shares Held
4,383
-33.3% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#138
of 211 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vinva Investment Management Ltd holds $143,806,233 across 13 Biotechnology names. ANAB ranks #11 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
462,843 | $52,467,882 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
154,972 | $46,651,221 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
34,494 | $21,508,388 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,687 | $15,243,153 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
24,835 | $1,943,835 | |
| 6 | EXEL |
Exelixis, Inc.
|
31,102 | $1,692,259 | |
| 7 | ASND |
Ascendis Pharma A/S
|
4,536 | $1,209,841 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
19,569 | $1,119,738 |
All Filings in ANAB
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $295,852 | 4,383 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $243,080 | 4,383 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||